SANTA CRUZ BIOTECHNOLOGY, INC.

PI 3-kinase p110α (H-201): sc-7174



BACKGROUND

Phosphatidylinositol 3-kinase (PI 3-kinase) is composed of p85 and p110 subunits. p85 lacks PI 3-kinase activity and acts as an adapter, coupling p110 to activated protein tyrosine kinase. Two forms of p85 have been described (p85 α and p85 β), each possessing one SH3 and two SH2 domains. Various p110 isoforms have been identified. p110 α and p110 β interact with p85 α , and p110 α has also been shown to interact with p85 β *in vitro*. p110 δ expression is restricted to white blood cells. It has been shown to bind p85 α and β , but it apparently does not phosphorylate these subunits. p110 δ seems to have the capacity to autophosphorylate. p110 γ does not interact with the p85 subunits. It has been shown to be activated by α and $\beta\gamma$ heterotrimeric G proteins.

CHROMOSOMAL LOCATION

Genetic locus: PIK3CA (human) mapping to 3q26.32; Pik3ca (mouse) mapping to 3 A3.

SOURCE

PI 3-kinase p110 α (H-201) is a rabbit polyclonal antibody raised against amino acids 189-390 mapping near the N-terminus of PI 3-kinase p110 α of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

PI 3-kinase p110 α (H-201) is recommended for detection of PI 3-kinase p110 α of mouse, rat, human and *Xenopus laevis* origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

PI 3-kinase p110 α (H-201) is also recommended for detection of PI 3-kinase p110 α in additional species, including equine, canine and bovine.

Suitable for use as control antibody for PI 3-kinase p110 α siRNA (h): sc-39127, PI 3-kinase p110 α siRNA (m): sc-39128, PI 3-kinase p110 α shRNA Plasmid (h): sc-39127-SH, PI 3-kinase p110 α shRNA Plasmid (m): sc-39128-SH, PI 3-kinase p110 α shRNA (h) Lentiviral Particles: sc-39127-V and PI 3-kinase p110 α shRNA (m) Lentiviral Particles: sc-39128-V.

Molecular Weight of PI 3-kinase p110a: 110 kDa.

Positive Controls: Jurkat whole cell lysate: sc-2204 or C32 whole cell lysate: sc-2205.


STORAGE


Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA





PL3-kinase p110\alpha (H-201): sc-7174. Immunofluo-

rescence staining of methanol-fixed HeLa cells

PI 3-kinase p110 α (H-201): sc-7174. Western blot analysis of PI 3-kinase p110 α expression in Jurkat whole cell lysate.

showing cytoplasmic and membrane localization

SELECT PRODUCT CITATIONS

- 1. Bi, L., et al. 1999. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110 α subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274: 10963-10968.
- Sasaki, R., et al. 2009. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis 30: 423-431.
- Fry, M.J. 2009. Phosphoinositide (PI) 3-kinase assays. Methods Mol. Biol. 462: 345-362.
- 4. Doi, T., et al. 2010. Disturbance of parathyroid hormone-related protein signaling in the nitrofen-induced hypoplastic lung. Pediatr. Surg. Int. 26: 45-50.
- Hohenester, S., et al. 2010. Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells. J. Hepatol. 53: 918-926.
- Xu, C., et al. 2011. Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth *in vitro* and *in vivo*. J. Exp. Clin. Cancer Res. 30: 63.
- Chen, C., et al. 2011. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J. Pharmacol. Exp. Ther. 336: 344-355.
- 8. Xu, X., et al. 2011. CYP2J3 gene delivery reduces Insulin resistance via upregulation of eNOS in fructose-treated rats. Cardiovasc. Diabetol. 10: 114.
- 9. Folli, F., et al. 2011. Altered Insulin receptor signalling and β -cell cycle dynamics in type 2 diabetes mellitus. PLoS ONE 6: e28050.

MONOS Satisfation Guaranteed

Try **PI 3-kinase p110\alpha (4F3): sc-293172**, our highly recommended monoclonal aternative to PI 3-kinase p110 α (H-201).